Srpske NovineSrpske Novine

Immune Cells Lure Nerves Into Breast Cancer

A University of Oklahoma team found that macrophages in breast cancer secrete BDNF to draw nerve fibers into the tumor. A drug already on the market stopped the process in mice.

Aleksandar Tomić4 min read0
Podeli
Microscopic image of aggressive breast cancer tissue, basal like subtype, stained with hematoxylin and eosin
Histopathology slide of the basal like breast cancer subtype, which largely overlaps with triple negative breast cancer/ Photo: Mikael Haggstrom / Wikimedia Commons

Researchers at the University of Oklahoma College of Medicine have described how triple negative breast cancer, or TNBC, pulls nerve fibers into its own tissue, with the recruiting done by immune cells that are supposed to defend the body, not serve a tumor. The study went online on July 2, 2026, in the journal Cell Death and Differentiation, and drew wider media attention in mid August, after the university issued a statement on the findings. The work was led by Maureen Cox, an assistant professor in the Department of Microbiology and Immunology and a researcher at the Stephenson Cancer Center. The paper’s first author is Jumana Abbadi.

Solid tumors have been known for years to contain branching networks of nerves, a pattern described across several cancer types. What has not been clear is how those nerves get there in the first place, since a nerve does not grow at random but follows a chemical signal. The Oklahoma study offers an answer for one specific and hard to treat form of the disease, triple negative breast cancer, which does not respond to the usual targeted therapies.

The Signal Macrophages Send

The tumor draws in macrophages, immune cells that normally help the body fight infection and heal wounds. Once inside the tumor, those macrophages start secreting a protein known as brain derived neurotrophic factor, or BDNF. The protein acts as a chemical beacon, prompting nearby nerve fibers to grow toward the tumor and enter it, a process called axonogenesis, the formation of new nerve extensions.

BDNF was until now best known for a very different role, supporting the growth and survival of nerve cells in the brain. The finding is that breast cancer hijacks that same signal for its own benefit, and the nerves that grow in then help the tumor grow further and resist treatment.

“Macrophages are a key source of nerve attraction into the tumor. While macrophages usually play a positive role in the body, in this breast cancer scenario they enable a negative function,” Maureen Cox said in the university’s statement.

That sentence sums up the treatment shift the team is proposing. Instead of attacking the tumor cell itself, a therapy could interrupt the conversation between macrophages and nerves.

A Drug Already on the Market, So Far Only in Mice

Cox and her colleagues tested that idea in mice. They used a drug that blocks BDNF signaling and is already on the market, and afterward nerves stopped growing into the tumors, while tumor growth slowed significantly.

“It’s promising that we may be able to use this drug, which is already on the market, to target BDNF,” Cox said. “We believe nerves are immunosuppressive, so if we can prevent nerves from growing in at all, we might be able to boost the immune response and help fight the cancer.”

To check whether the same pattern holds up in people, the researchers analyzed data from triple negative breast cancer patients. Tumors with a higher share of macrophages and higher BDNF levels were linked to worse survival.

The work was funded by the National Institute of General Medical Sciences through awards P20GM103447 and P20GM103639, the Oklahoma Tobacco Settlement Endowment Trust, and a shared clinical resources program under grant U54GM104938.

Why Would Nerves in a Tumor Even Matter?

The team is still looking for that answer. Some of the existing evidence points to nerves promoting the formation of blood vessels, which supply the tumor with oxygen and nutrients. Other evidence points to tumor cells traveling along nerves when they leave their original site and form metastases.

Neither possibility is confirmed by this study, they are a framework for the next step. The team plans to test the same approach in high grade ovarian cancer, another form of the disease that is difficult to treat.

“Ultimately, we want to switch antitumor immunity back on in cancer patients, so their own immune system rejects the tumors,” Cox said.

What This Does Not Prove

The result is preclinical. Blocking BDNF stopped nerves from growing in and slowed tumor growth in mice, not in patients, and that is a line the study does not cross. No clinical trial of this therapy in humans has been reported, so the paper cannot say what dose would be needed or what side effects would follow from blocking a protein that serves a useful purpose in the brain.

The human part of the study is an observation of existing data, not an experiment. Tumors with more macrophages and more BDNF were associated with worse survival, which is not the same as proof that the combination causes the worse outcome. The finding also applies to one subtype of the disease, so it does not automatically carry over to other forms of breast cancer.

It is also the work of a single research group and one set of experiments. Until an independent team repeats the finding, and until the drug is tested in humans for this indication, the mechanism is a convincingly described path, not a therapy.

Podeli
Komentari…
Next storyCyber Knife at VMA: Which Tumors and How to Get ReferredThe robotic radiation system has been running at VMA since October 1. Which tumors it treats, who pays and what a referral needs, per the VMA deputy chief.

From other sections

Most read today

  1. Greece vs Serbia: Zivkovic and Dragojevic Out in Volos
  2. Air Serbia Bars Montenegrin Fans From Larnaca Flight
  3. Student List to Elect Assembly Speaker by Majority Vote
  4. Stevandic re-elected Republika Srpska parliament speaker
  5. Guard says it targeted US radar in Bahrain

Komentari (0)

Ostavi komentar

Komentari prolaze kratku moderaciju. Lični napadi i govor mržnje se brišu.

Još nema komentara. Budi prvi i podeli mišljenje.